neurology

News

NICE says no to Novartis’ Mayzent in secondary progressive M...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this

News

Akili's ADHD digital therapy approved in Europe

The European Medicines Agency has approved Akili’s ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD), which uses a video game to treat the underlying cause

News

Lilly announces CNS tie-up with UK biotech Evox Therapeutics

Eli Lilly has announced a central nervous system research tie-up with UK biotech Evox Therapeutics, which focuses on drug engineering using vesicles to deliver drugs to targets.

News

Lundbeck announces plans to cut a fifth of R&D workforce

Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of up to 160 jobs from an 800-strong department.

News

Novartis offers reimbursement options as EU backs costly SMA...

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA),

News

Takeda posts surprise profit a year after Shire mega-merger

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done.

NICE says no to Novartis’ Mayzent in secondary progressive M...

Akili's ADHD digital therapy approved in Europe

Lilly announces CNS tie-up with UK biotech Evox Therapeutics

Lundbeck announces plans to cut a fifth of R&D workforce

Novartis offers reimbursement options as EU backs costly SMA...

Takeda posts surprise profit a year after Shire mega-merger

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

neurology

Editor's Picks